PMID- 27518403
OWN - NLM
STAT- MEDLINE
DCOM- 20170126
LR  - 20181202
IS  - 1432-8798 (Electronic)
IS  - 0304-8608 (Linking)
VI  - 161
IP  - 11
DP  - 2016 Nov
TI  - Efficacy and safety of interferon-alpha2b spray in the treatment of hand, foot, and 
      mouth disease: a multicenter, randomized, double-blind trial.
PG  - 3073-80
LID - 10.1007/s00705-016-3012-7 [doi]
AB  - Hand, foot, and mouth disease (HFMD) is a common infectious enterovirus disease, 
      occurring mostly in infants and children younger than 7 years with potentially 
      fatal complications. Therefore, we evaluated the clinical efficacy and safety of 
      recombinant human interferon (IFN)-alpha2b spray for treating mild HFMD in 400 
      patients in a randomized, open, controlled clinical trial. The patients were 
      randomized to the IFN-alpha2b spray and placebo groups, and their temperature, skin 
      rash, oral lesions, and appetite were monitored, while pathogen levels and safety 
      were evaluated with a 7-day follow-up. The mean age of the patients was 
      20.1 +/- 10.2 months. The median duration of fever, oral ulcers or vesicles (or 
      both), and skin rash in addition to median time to regain appetite in the IFN-alpha2b 
      spray group were shorter than they were in the placebo group. The number of 
      virus-positive cases differed statistically between the two groups for the three 
      follow-up detections. Additionally, the incidences of adverse events (AEs) and 
      severe AEs (SAEs) were not significantly different between the two groups, and 
      the SAEs were evidently unrelated to the IFN-alpha2b spray or placebo. Therefore, the 
      IFN-alpha2b spray is suitable for topical treatment of HFMD, and it rapidly relieved 
      fever, promoted oral lesions and subsidence of rash, enhanced appetite, promoted 
      disease recovery, and was safe for application.
FAU - Lin, Hailong
AU  - Lin H
AD  - Department of Pediatric Infection, The Second Affiliated Hospital of Wenzhou 
      Medical University, 109th Xueyuanxi Road, Wenzhou, Zhejiang, China.
FAU - Huang, Leting
AU  - Huang L
AD  - Department of Pediatric Infection, The Second Affiliated Hospital of Wenzhou 
      Medical University, 109th Xueyuanxi Road, Wenzhou, Zhejiang, China.
FAU - Zhou, Jian
AU  - Zhou J
AD  - Department of Pediatrics, The first people's Hospital of Yongkang, Jinhua, China.
FAU - Lin, Kaichun
AU  - Lin K
AD  - Department of Pediatrics, The first people's Hospital of Yongkang, Jinhua, China.
FAU - Wang, Hongjiao
AU  - Wang H
AD  - Department of Pediatrics, The Affiliated Children's Hospital of Zhejiang 
      University Medical College, Hangzhou, China.
FAU - Xue, Xia
AU  - Xue X
AD  - Department of Pediatrics, The Affiliated Children's Hospital of Zhejiang 
      University Medical College, Hangzhou, China.
FAU - Xia, Chan
AU  - Xia C
AUID- ORCID: 0000-0002-1666-6339
AD  - Department of Pediatric Infection, The Second Affiliated Hospital of Wenzhou 
      Medical University, 109th Xueyuanxi Road, Wenzhou, Zhejiang, China. 
      lanqi20@163.com.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20160812
PL  - Austria
TA  - Arch Virol
JT  - Archives of virology
JID - 7506870
RN  - 0 (Aerosols)
RN  - 0 (Antiviral Agents)
RN  - 0 (Interferon alpha-2)
RN  - 0 (Interferon-alpha)
RN  - 0 (Placebos)
RN  - 0 (Recombinant Proteins)
SB  - IM
MH  - Aerosols/*administration & dosage
MH  - Antiviral Agents/*administration & dosage/adverse effects
MH  - Child, Preschool
MH  - Double-Blind Method
MH  - Female
MH  - Hand, Foot and Mouth Disease/*drug therapy/pathology
MH  - Humans
MH  - Infant
MH  - Interferon alpha-2
MH  - Interferon-alpha/*administration & dosage/adverse effects
MH  - Male
MH  - Placebos/administration & dosage
MH  - Recombinant Proteins/administration & dosage/adverse effects
MH  - Treatment Outcome
EDAT- 2016/08/16 06:00
MHDA- 2017/01/27 06:00
CRDT- 2016/08/13 06:00
PHST- 2016/05/16 00:00 [received]
PHST- 2016/08/07 00:00 [accepted]
PHST- 2016/08/13 06:00 [entrez]
PHST- 2016/08/16 06:00 [pubmed]
PHST- 2017/01/27 06:00 [medline]
AID - 10.1007/s00705-016-3012-7 [pii]
AID - 10.1007/s00705-016-3012-7 [doi]
PST - ppublish
SO  - Arch Virol. 2016 Nov;161(11):3073-80. doi: 10.1007/s00705-016-3012-7. Epub 2016 
      Aug 12.